Rapid Novor Protein Characterization Technology2024-06-05T10:57:59-04:00

Our Technology.

Our services are built on our proprietary software for Next Generation Protein Sequencing and patented chemistry. Read on to learn about how it works and our ongoing advances in antibody sequencing, discovery and characterization technology.

We encourage you to dive into more of our resources below. Contact us for more information.


Integrating AI and HDX-MS for Antibody Epitope Mapping

July 11 2024, 10:00AM EST | 16:00 CET

Latest Posts



Key Pain Points in Amino Acid Sequencing & How to Avoid Them

Amino acid sequencing is commonly performed using Edman degradation or mass spectrometry (MS). While mass spectrometry is favoured for its high throughput capabilities and ease of use, both techniques possess their own features and limitations. This article summarizes some of the key pain points inherent in the two methodologies when determining the amino acid sequence.

De Novo Protein Sequencing vs DNA Sequencing

DNA sequencing is the process of determining the precise order of four nucleotides bases—adenine (A), guanine (G), cytosine (C), and thymine (T)—that make up the DNA molecule. From Sanger sequencing to next-generation sequencing (NGS), DNA sequencing’s accessibility and ease of use make it one of the most widely used technologies in life sciences.

How to Determine Peptide Sequences

Amino acids (aa)—the building blocks of proteins—are simple molecules characterized by a variable R group flanked either side by an amino group and a carboxyl group. With around 20 different commonly found amino acids, each one can bond with another to produce chains that can be classified as peptides (typically below 50 aa) and proteins (sequences above 50 aa)—molecules ubiquitous to every known organism.

Why is Protein Sequencing Useful?

Protein sequencing is a method that typically utilizes mass spectrometry (MS) to determine the amino acid code of a protein1. Prior to the development of mass spectrometry, Edman degradation, a method involving the stepwise degradation of peptides to derive the order of amino acids, was the mainstream approach. Nowadays, mass spectrometry is favored due to its ease of use and high throughput capabilities, though Edman degradation is still employed for specific applications in which the technique is well suited.

What is Protein Sequencing by Mass Spectrometry?

Nowadays, DNA sequencing is so popular that it is easy to forget that the first sequenced biological material was protein – insulin, by Sanger. Sanger, and another researcher, Edman, separately pioneered protein sequencing.

Antibody Protein Sequence Analysis Using Mass Spectrometry

One of the most important pieces of information researchers need to know during early stage antibody drug research and development is the sequence information of the antibody protein. With the advancement of mass spectrometry instrumentation and technologies, it is helpful, and sometimes critical, to conduct sequence analysis using mass spectrometry experiments.

Isoleucine and Leucine

Because they share the same mass, isoleucine and leucine are known as isobaric amino acids. Conventional mass spectrometry-based proteomics cannot be easily used to distinguish between isoleucine and leucine.

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

DNA Sequencing vs Next Generation Protein Sequencing

The protein sequence is key to understanding the function of a protein target and is critical to therapeutic and diagnostic development. This is particularly important for antibodies whose code diversity and glycosylation impact both function, and stability.

Enhanced Antibody Engineering for Development of Therapeutic Antibodies

Mouse monoclonal antibodies (mAbs) are highly attractive for manipulation for therapeutic applications as their manufacturing is relatively easy and well-established compared to mAbs derived from larger animal models. However, they also pose several challenges which limit their use as therapeutic agents.

The Underlying Cause of Medical Diagnostic Invalidation

In-vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.

Recombinant Antibodies: A New Generation Enabled by Protein Sequencing

Recombinant antibodies are artificially synthesized antibodies. Recombinant antibodies are generated from expression systems (e.g., E.coli, yeast, mammalian cell lines) via transfection with two separate plasmids encoding the amino acid sequences for the light and heavy chains, respectively. In order to recombinantly produce mAbs, the amino acid sequence of the light and heavy chains must be known. There are many ways to obtain the sequence of an antibody.

Identifying CDRs by Antibody Sequencing

The acronym “CDR” stands for complementarity determining region, a variable sequence of amino acids that folds into loops capable of binding to an antigenic amino acid sequence, also known as an epitope

Introduction to De Novo Protein Sequencing

In this on-demand webinar, our scientific sales executive Jennifer, will briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein sequencing into their pipelines, and discuss how Rapid Novor is able to routinely and robustly achieve 100% accuracy and 100% coverage for both monoclonal and oligoclonal antibodies.

Leveraging Recombinant Patient Antibodies in Therapeutic Applications

Our team has perfected the art of monoclonal antibody sequencing and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony will walk through our new polyclonal sequencing platform that uses both proteomics and genomics to sequence the most abundant antibodies found in polyclonal sera.

Research Insurance with De Novo Protein Sequencing

If you could have guaranteed stability, certainty, and reproducibility for your research, would you be interested? Imagine this, if you’re 2 years into your project and your freezer died along with all of your important cell lines, what would you do? This is just one of the situations covered in this webinar, along with many other solutions researchers have begun to implement to safeguard their efforts. Whether you’re looking to proceed with stability and certainty or you’re looking for an immediate solution for your current reproducibility challenges, protein sequencing may be the answer.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.